DexCom, Inc. (NASDAQ:DXCM) EVP Donald Abbey sold 5,843 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.85, for a total value of $875,573.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ:DXCM traded up $1.46 on Wednesday, hitting $146.70. 911,812 shares of the company’s stock were exchanged, compared to its average volume of 1,200,108. DexCom, Inc. has a 1-year low of $105.05 and a 1-year high of $178.45. The company has a market capitalization of $13.26 billion, a PE ratio of 489.00 and a beta of 0.72. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The firm’s 50-day moving average is $160.01 and its 200 day moving average is $139.33.
DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.07. The firm had revenue of $336.40 million during the quarter, compared to analysts’ expectations of $304.40 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm’s revenue was up 38.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.10) earnings per share. On average, analysts anticipate that DexCom, Inc. will post 0.94 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Gradient Investments LLC purchased a new position in shares of DexCom in the 2nd quarter valued at $25,000. Virtus ETF Advisers LLC acquired a new stake in DexCom during the 2nd quarter worth $29,000. CSat Investment Advisory L.P. purchased a new stake in DexCom in the second quarter valued at $31,000. Steward Partners Investment Advisory LLC purchased a new stake in DexCom in the second quarter valued at $31,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in DexCom in the second quarter valued at $37,000. Institutional investors and hedge funds own 96.79% of the company’s stock.
Several research firms recently issued reports on DXCM. Oppenheimer increased their target price on DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. Robert W. Baird lifted their target price on DexCom from $186.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Northland Securities reiterated a “hold” rating and set a $125.00 price target on shares of DexCom in a research note on Thursday, June 6th. BMO Capital Markets increased their price target on shares of DexCom from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Finally, TheStreet raised shares of DexCom from a “d+” rating to a “c” rating in a research note on Friday, June 28th. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $168.44.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.